• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Arteriosclerosis - Pipeline Review, H2 2012 Product Image

Arteriosclerosis - Pipeline Review, H2 2012

  • Published: December 2012
  • 265 pages
  • Global Markets Direct

Arteriosclerosis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Arteriosclerosis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Arteriosclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Arteriosclerosis. Arteriosclerosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Arteriosclerosis.
- A review of the Arteriosclerosis products under development by companies and universities/research institutes READ MORE >

2
List of Tables 7
List of Figures 9
Introduction 10
REPORT COVERAGE 10
Arteriosclerosis Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Arteriosclerosis 12
Arteriosclerosis Therapeutics under Development by Companies 14
Arteriosclerosis Therapeutics under Investigation by Universities/Institutes 19
Late Stage Products 22
Comparative Analysis 22
Mid Clinical Stage Products 23
Comparative Analysis 23
Early Clinical Stage Products 24
Comparative Analysis 24
Discovery and Pre-Clinical Stage Products 25
Comparative Analysis 25
Arteriosclerosis Therapeutics – Products under Development by Companies 26
Arteriosclerosis Therapeutics – Products under Investigation by Universities/Institutes 31
Companies Involved in Arteriosclerosis Therapeutics Development 33
Bristol-Myers Squibb Company 33
Eli Lilly and Company 34
GlaxoSmithKline plc 35
Isis Pharmaceuticals, Inc. 36
Merck & Co., Inc. 37
Otsuka Pharmaceutical Co., Ltd. 38
Novartis AG 39
Dr. Reddy's Laboratories Limited 40
Kowa Company, Ltd. 41
Zydus Cadila Healthcare Limited 42
TCA Cellular Therapy 43
Merck KGaA 44
Genfit 45
PROLOR Biotech, Inc. 46
Novogen Limited 47
CSL Limited 48
Yuhan Corporation 49
Bio3 Research S.r.l 50
BioInvent International AB 51
Hanall Pharmaceutical Co., Ltd. 52
Cytos Biotechnology AG 53
Resverlogix Corp. 54
LTT Bio-Pharma Co., Ltd. 55
CytoTools AG 56
Pronova BioPharma ASA 57
e-Therapeutics plc 58
Angelini Group 59
AFFiRiS AG 60
Avanti Therapeutics 61
Jenrin Discovery, Inc. 62
Phosphagenics Limited 63
Xenon Pharmaceuticals Inc. 64
Spherix Incorporated 65
Arisaph Pharmaceuticals, Inc. 66
GenKyoTex S.A. 67
Vascular Biogenics Ltd. 68
Cardax Pharmaceuticals, Inc. 69
KineMed, Inc. 70
BRIDGE BIORESEARCH PLC 71
ChemoCentryx, Inc. 72
CBio Limited 73
Provid Pharmaceuticals, Inc. 74
Vitae Pharmaceuticals, Inc. 75
Resolvyx Pharmaceuticals, Inc 76
Athera Biotechnologies AB 77
NasVax Ltd. 78
Regulus Therapeutics Inc. 79
Centocor Ortho Biotech, Inc. 80
Esperion Therapeutics, Inc. 81
SelectX Pharmaceuticals, Inc. 82
InVasc Therapeutics, Inc. 83
Artery Therapeutics, Inc. 84
Arteriosclerosis – Therapeutics Assessment 85
Assessment by Monotherapy Products 85
Assessment by Combination Products 86
Assessment by Route of Administration 87
Assessment by Molecule Type 89
Drug Profiles 92
anacetrapib - Drug Profile 92
BI-204 - Drug Profile 94
LXR Modulators - Drug Profile 96
MK-0524A - Drug Profile 98
darapladib - Drug Profile 100
vorapaxar - Drug Profile 102
canakinumab - Drug Profile 104
SOL-02 - Drug Profile 107
LT-0101 - Drug Profile 108
ecraprost - Drug Profile 109
CT-406 - Drug Profile 110
DRL-17822 - Drug Profile 112
APA-01 + Atorvastatin - Drug Profile 114
SPX-7233801 - Drug Profile 115
NV-27 - Drug Profile 116
Trans NV-04 - Drug Profile 117
VB-201 - Drug Profile 118
REV D-4F - Drug Profile 120
Lipase Inhibitors - Drug Profile 121
K-134 - Drug Profile 122
K-604 - Drug Profile 123
Cardiovascular Program - Drug Profile 124
RVX-208 - Drug Profile 125
CSL-112 - Drug Profile 127
salsalate - Drug Profile 128
RX-10001 - Drug Profile 129
Simvastatin + Niacin - Drug Profile 131
rifalazil - Drug Profile 133
JD-2000 Series - Drug Profile 135
ETC-1002 - Drug Profile 136
JD-5000 Series - Drug Profile 138
JD-6000 Series - Drug Profile 139
ETX-6107 - Drug Profile 140
CYT-018-IL1aQb - Drug Profile 141
MDCO-216 - Drug Profile 142
AT-5261 - Drug Profile 144
GKT-137831 - Drug Profile 145
CDX-085 - Drug Profile 146
XToll - Drug Profile 148
losmapimod - Drug Profile 150
Atorvastatin + Aspirin - Drug Profile 152
Simvastatin + Aspirin - Drug Profile 153
rosuvastatin calcium - Drug Profile 154
BMS-823778 - Drug Profile 155
MK-0653C - Drug Profile 157
valsartan - Drug Profile 159
Mesendo - Drug Profile 160
Clopidogrel + Aspirin - Drug Profile 162
aliskiren hemifumarate - Drug Profile 164
PPARgamma Modulators - Drug Profile 166
pioglitazone hydrochloride - Drug Profile 167
aliskiren - Drug Profile 168
evacetrapib - Drug Profile 169
INV-404 - Drug Profile 171
INV-405 - Drug Profile 172
ATH-03 - Drug Profile 173
niacin ER - Drug Profile 174
Drug For Atherosclerotic Plaque - Drug Profile 176
Annexin A5 - Drug Profile 177
Anti-aCD3 Mab - Drug Profile 178
Protein-Based HDL Therapies - Drug Profile 180
Anti-miR-33a/b - Drug Profile 182
SPX-106T - Drug Profile 184
Clopidogrel + Everolimus - Drug Profile 186
CD14 Project - Drug Profile 187
PRC-4016 - Drug Profile 188
polyarginine - Drug Profile 189
AHRO-001 - Drug Profile 190
AHRO-001 - Drug Profile 191
Drug For Atherosclerosis - Drug Profile 192
ISIS-APOARx - Drug Profile 193
YH-Chem3 - Drug Profile 194
prednisolone sodium phosphate - Drug Profile 195
ATAS-123 - Drug Profile 196
Anti-Arteriosclerotic Drug - Drug Profile 197
ACP-501 - Drug Profile 198
AS-605240 - Drug Profile 200
Drug Targeting F11R - Drug Profile 202
CideB Antisense Oligonucleotide - Drug Profile 204
S002-333 - Drug Profile 205
Vaccine For Atherosclerosis - Drug Profile 206
KRP-206 - Drug Profile 207
CCX-771 - Drug Profile 208
Anti-PC IgG - Drug Profile 209
Drug For Baroreflex Activity - Drug Profile 211
Progranulin - Drug Profile 212
VTP-4 - Drug Profile 213
microRNA-145-Based Gene Therapy - Drug Profile 214
VPI-2690B - Drug Profile 215
FX-5A - Drug Profile 216
Cell Migration Inhibitors - Drug Profile 217
ATI-829 - Drug Profile 218
Arteriosclerosis Therapeutics – Drug Profile Updates 219
Arteriosclerosis Therapeutics – Discontinued Products 244
Arteriosclerosis Therapeutics - Dormant Products 246
Arteriosclerosis – Product Development Milestones 252
Featured News & Press Releases 252
Appendix 258
Methodology 258
Coverage 258
Secondary Research 258
Primary Research 258
Expert Panel Validation 258
Contact Us 259
Disclaimer 259

List of Tables
Number of Products Under Development for Arteriosclerosis, H2 2012 18
Products under Development for Arteriosclerosis – Comparative Analysis, H2 2012 19
Number of Products under Development by Companies, H2 2012 21
Number of Products under Development by Companies, H2 2012 (Contd..1) 22
Number of Products under Development by Companies, H2 2012 (Contd..2) 23
Number of Products under Development by Companies, H2 2012 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H2 2012 26
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 27
Comparative Analysis by Late Stage Development, H2 2012 28
Comparative Analysis by Mid Clinical Stage Development, H2 2012 29
Comparative Analysis by Early Clinical Stage Development, H2 2012 30
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 31
Products under Development by Companies, H2 2012 32
Products under Development by Companies, H2 2012 (Contd..1) 33
Products under Development by Companies, H2 2012 (Contd..2) 34
Products under Development by Companies, H2 2012 (Contd..3) 35
Products under Development by Companies, H2 2012 (Contd..4) 36
Products under Investigation by Universities/Institutes, H2 2012 37
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 38
Bristol-Myers Squibb Company, H2 2012 39
Eli Lilly and Company, H2 2012 40
GlaxoSmithKline plc, H2 2012 41
Isis Pharmaceuticals, Inc., H2 2012 42
Merck & Co., Inc., H2 2012 43
Otsuka Pharmaceutical Co., Ltd., H2 2012 44
Novartis AG, H2 2012 45
Dr. Reddy's Laboratories Limited, H2 2012 46
Kowa Company, Ltd., H2 2012 47
Zydus Cadila Healthcare Limited, H2 2012 48
TCA Cellular Therapy, H2 2012 49
Merck KGaA, H2 2012 50
Genfit, H2 2012 51
PROLOR Biotech, Inc., H2 2012 52
Novogen Limited, H2 2012 53
CSL Limited, H2 2012 54
Yuhan Corporation, H2 2012 55
Bio3 Research S.r.l, H2 2012 56
BioInvent International AB, H2 2012 57
Hanall Pharmaceutical Co., Ltd., H2 2012 58
Cytos Biotechnology AG, H2 2012 59
Resverlogix Corp., H2 2012 60
LTT Bio-Pharma Co., Ltd., H2 2012 61
CytoTools AG, H2 2012 62
Pronova BioPharma ASA, H2 2012 63
e-Therapeutics plc, H2 2012 64
Angelini Group, H2 2012 65
AFFiRiS AG, H2 2012 66
Avanti Therapeutics, H2 2012 67
Jenrin Discovery, Inc., H2 2012 68
Phosphagenics Limited, H2 2012 69
Xenon Pharmaceuticals Inc., H2 2012 70
Spherix Incorporated, H2 2012 71
Arisaph Pharmaceuticals, Inc., H2 2012 72
GenKyoTex S.A., H2 2012 73
Vascular Biogenics Ltd., H2 2012 74
Cardax Pharmaceuticals, Inc., H2 2012 75
KineMed, Inc., H2 2012 76
BRIDGE BIORESEARCH PLC, H2 2012 77
ChemoCentryx, Inc., H2 2012 78
CBio Limited, H2 2012 79
Provid Pharmaceuticals, Inc., H2 2012 80
Vitae Pharmaceuticals, Inc., H2 2012 81
Resolvyx Pharmaceuticals, Inc, H2 2012 82
Athera Biotechnologies AB, H2 2012 83
NasVax Ltd., H2 2012 84
Regulus Therapeutics Inc., H2 2012 85
Centocor Ortho Biotech, Inc., H2 2012 86
Esperion Therapeutics, Inc., H2 2012 87
SelectX Pharmaceuticals, Inc., H2 2012 88
InVasc Therapeutics, Inc., H2 2012 89
Artery Therapeutics, Inc., H2 2012 90
Assessment by Monotherapy Products, H2 2012 91
Assessment by Combination Products, H2 2012 92
Assessment by Stage and Route of Administration, H2 2012 94
Assessment by Stage and Molecule Type, H2 2012 97
Arteriosclerosis Therapeutics – Drug Profile Updates 225
Arteriosclerosis Therapeutics – Discontinued Products 250
Arteriosclerosis Therapeutics – Discontinued Products (Contd..1) 251
Arteriosclerosis Therapeutics – Dormant Products 252
Arteriosclerosis Therapeutics – Dormant Products (Contd..1) 253
Arteriosclerosis Therapeutics – Dormant Products (Contd..2) 254
Arteriosclerosis Therapeutics – Dormant Products (Contd..3) 255
Arteriosclerosis Therapeutics – Dormant Products (Contd..4) 256
Arteriosclerosis Therapeutics – Dormant Products (Contd..5) 257

List of Figures
Number of Products under Development for Arteriosclerosis, H2 2012 18
Products under Development for Arteriosclerosis – Comparative Analysis, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 25
Late Stage Products, H2 2012 28
Mid Clinical Stage Products, H2 2012 29
Early Clinical Stage Products, H2 2012 30
Discovery and Pre-Clinical Stage Products, H2 2012 31
Assessment by Monotherapy Products, H2 2012 91
Assessment by Combination Products, H2 2012 92
Assessment by Route of Administration, H2 2012 93
Assessment by Stage and Route of Administration, H2 2012 94
Assessment by Molecule Type, H2 2012 95
Assessment by Stage and Molecule Type, H2 2012 96

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos